';
HomeBiomnis LiveShedding light on“Solid Tumour” gene panels

Shedding light on

See all "Shedding light on"

“Solid Tumour” gene panels

Pictogramme horloge Benoit QUILICHINI Pictogramme horloge December 2020

New molecular panels for theranostic and/or prognostic purposes enabling several genes involved in solid tumours to be analysed simultaneously by NGS.

For the therapeutic management of certain solid tumours, cytogenetic (FISH) and molecular biology techniques are indispensable – therefore, the term “companion test” for targeted therapy is commonly used. For the past ten years, these molecular tests have been offered at Eurofins Biomnis in an isolated test format (e.g. EGFR, KRAS, NRAS or BRAF).

Therapeutic management in the field of solid oncology is progressing at lightening speed and requires providing the clinician with increasingly precise and personalised information: prognostic value of a mutation, sensitivity or resistance associated with a mutation for a targeted therapy and for a given type of tumour, or the identification of mutations of acquired resistance secondary to a targeted treatment.

Eurofins Biomnis’ new global offer in solid oncology responds to this demand and in particular the “NGS – Solid Tumours” offer.

The laboratory now offers various gene panels analysed by high-throughput sequencing (NGS). This technique allows the molecular characterisation of tumours by simultaneously analysing several genes (from 3 to 24) involved in carcinogenesis.

These panels are dedicated to each organ (e.g. lung, colon, etc.) to facilitate their prescription and extended NGS panels are also available to analyse emerging markers of targeted therapies (monoclonal antibodies and tyrosine kinase inhibitors) or secondary molecular markers of resistance.

Complementary molecular tests are also available to complete this NGS offer: MSI test, targeted FISH test, etc.
This “NGS Solid Tumours” offer is an extension of the “NGS Haematological Malignancies” offer performed by the laboratory since April 2019:

Organ / DiseasePanelTest CodeTurnaround time
LUNGLUNG Panel 1 (4 genes)
EGFR – BRAF – MET- KRAS
POUM110 days
LUNG Panel 2 (19 genes)
AKT1 – ALK – BRAF – DDR2 – EGFR – HER2 – FGFR1 – FGFR2 – FGFR3 – KIT – KRAS – MAP2K1 – MET – NRAS – PDGFRA – PIK3CA – PTEN – STK11 – TP53
POUM210 days
COLORECTALCOLO-RECTAL Panel  1 (3 genes)
KRAS – NRAS – BRAF
COLO110 days
COLORECTAL Panel 2 (21 genes)
AKT1 – ALK – BRAF – CTNNB1 – EGFR – HER2 – FBXW7 – FGFR1 – FGFR2 – FGFR3 – KIT – KRAS – MAP2K1 – MET – NRAS – PDGFRA – PIK3CA – PTEN – SMAD4 – STK11 – TP53
COLO210 days
GISTGIST Panel (3 genes)
KIT – PDGFRA – BRAF
GIST10 days
MELANOMAMELANOMA Panel (3 genes)
BRAF- NRAS – KIT
MELA10 days
PAN ORGANEPAN ORGAN Panel (24 genes)
AKT1 – ALK – BRAF – CTNNB1 – DDR2 – EGFR – HER2 – HER4 – FBXW7 – FGFR1 – FGFR2 – FGFR3 – KIT – KRAS – MAP2K1- MET – NOTCH1 – NRAS – PDGFRA – PIK3CA – PTEN – SMAD4 – STK11 – TP53
PAN10 days

These molecular techniques are interpreted by a clinical pathologist in close collaboration with our anatomical pathologists.

The above-mentioned gene panels are made from DNA extracted from tumour tissue. It should be noted that the quality of interpretation of these tests depends directly on the pre-analytical conditions of the sample (ischaemia time, type of fixative and fixation time), the reagents used and the robustness of the molecular biology technique chosen.


For more information

Clinical Data Sheets

Reference

WHO Classification of Tumours – Books catalog – IARC Lyon


Mettez à jour votre navigateur pour consulter ce site